Kornimate/medical-research-clean huggingface dataset:
the role of modified ultrafiltration following open heart surgery

Conditions: Heart; Surgery, Heart, Functional Disturbance as Result

Summary: this study aims to investigate the effect of combining conventional ultrafiltration and modified ultrafiltration compared to conventional ultrafiltration alone in patients who underwent open heart surgery.

the target of this study is adult patients diagnosed with coronary heart disease and valve disease who underwent open heart surgery in cicu pjt rscm and jakarta heart hospital. the research was conducted after obtaining approval from the fkui-rscm ethical committee, and the research subjects agreed to participate by signing an informed consent form. the anesthesia team prepared research subjects undergoing surgery with the placement of arterial cannulas, central venous catheters, sheath introducers, pulmonary artery catheters, and anesthesia management. the placement of these instruments aimed at measuring dependent variables studied included systemic vascular resistance (svr), pulmonary vascular resistance (pvr), cardiac index (ci), and il-6 levels. the cpb machine was used during the heart chamber opening procedure or coronary artery graft placement, and cuf was initiated. after cpb use was concluded, research subjects were allocated to either the control group or the treatment group through randomization. muf was performed post-cpb in the treatment group, with the pump speed not exceeding 10% of full flow for 10 minutes. il-6 levels were measured twice, namely before induction of anesthesia and 24 hours after cpb. svr, pvr, and ci measurements were carried out before cpb, post-cpb, 10 minutes post-cpb, and 24 hours post-cpb.

Eligibility criteria:
inclusion criteria: * adult patients aged 18 years or older undergoing elective open heart surgery * willing to become a research participant and sign an informed consent statement exclusion criteria: * patients undergoing redo surgery and emergency surgery * patients that have immune disease, chronic lung disease, undergoing hemodialysis * patients who are pregnant drop-out criteria * patients who experience repeated back-on bypass * patients who experience reopen surgery 24 hours after surgery * patients who die within 24 hours after surgery

Keywords: cardiopulmonary bypass conventional ultrafiltration modified ultrafiltration systemic vascular resistance pulmonary vascular resistance cardiac output index interleukin-6
locally produced cloth face mask and covid-19 like illness prevention

Conditions: COVID-19; Respiratory Illness

Summary: the number of cases of covid-19 is still increasing and transmission of sars-cov-2 seems to occur mainly through person-to-person transmission through respiratory droplets, indirect contact with infected people and surfaces. the use of face masks is recommended as a public health measure, but in many settings only domestic cloth made masks are available to the majority of the people. however, masks can be of different quality and very little is known about the utility of cloth face masks at the community level. in bandim health project's health and demographic surveillance system we will evaluate the effect of providing locally produced cloth face masks on severity of covid-19 like illness and mortality in an urban population. the locally produced cloth mask is made according to a laboratory certified model and will be provided to the intervention group alongside information of how the risk of transmission can be reduced. the control group will receive information alone. follow-up will be implemented through telephone calls and post-epidemic home visits.


Eligibility criteria:
inclusion criteria: * household resident * age: 10 years and older exclusion criteria: * refusal to participate

Keywords: face mask covid-19 respiratory illness mortality
premedication to reduce amivantamab associated infusion related reactions

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: the purpose of the study is to separately assess the potential of dexamethasone, montelukast and methotrexate administration, prior to amivantamab infusion given through a needle in the vein, to decrease the incidence and/or severity of first-dose infusion related reactions.


Eligibility criteria:
inclusion criteria: * participant must have advanced or metastatic non-small cell lung cancer (nsclc) * eastern cooperative oncology group (ecog) performance status grade of 0 or 1 * a female participant using oral contraceptives must use an additional barrier contraceptive method * a male participant must wear a condom when engaging in any activity that allows for passage of ejaculate to another person during the study and for 3 months after receiving the last dose of study treatment, oral lazertinib and intravenous (iv) amivantamab * each participant, or legally authorized representative, where allowed, must sign an informed consent form (icf) indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the study * progressed on or after prior treatment with osimertinib and platinum-based chemotherapy. prior use of first-or-second generation epidermal growth factor receptor tyrosine kinase inhibitor (egfr tki) is allowed if administered prior to osimertinib * previously identified egfr-mutated non-small cell lung cancer (nsclc) (egfr exon19 deletion or l858r) (identified locally in a clinical laboratory improvement amendments \[clia\]-certified laboratory \[or equivalent\]) exclusion criteria: * participant has a medical history of interstitial lung disease (ild), including drug-induced ild or radiation pneumonitis * prior treatment with anti pd-1 or anti pd-l1 antibody within 6 weeks of planned first dose of study treatment or immune-mediated rash from checkpoint inhibitors that has not resolved prior to enrollment * participant has symptomatic brain metastases. a participant with asymptomatic or previously treated and stable brain metastases may participate in this study. participants who have completed definitive therapy, are not on steroids, and have a stable clinical status for at least 2 weeks prior to study treatment are allowed. if brain metastases are diagnosed on screening imaging, the participant may be enrolled, or rescreened for eligibility, after definitive treatment if above criteria are met * any toxicities from prior anticancer therapy must have resolved to common terminology criteria for adverse events (ctcae) version 5.0 grade 1 or baseline level (except for alopecia \[any grade\], grade less than or equal to \[\<=\] 2 peripheral neuropathy, and grade \<=2 hypothyroidism stable on hormone replacement therapy) * prior treatment with amivantamab or lazertinib
dcvac/ovca after standard-of-care chemotherapy in women with relapse of platinum-sensitive epithelial ovarian cancer

Conditions: Ovarian Cancer Recurrent

Summary: the purpose of this trial is to investigate if maintenance dcvac/ovca after second-line chemotherapy of carboplatin/gemcitabine or carboplatin/paclitaxel improves efficacy outcomes in women with figo stage iii and iv epithelial ovarian carcinoma who experienced relapse more than 6 months after complete remission of first line platinum-based chemotherapy (platinum sensitive ovarian cancer)

all patients who fulfill all eligibility criteria will undergo a leukapheresis procedure. all eligible/enrolled patients will receive standard-of-care therapy with carboplatin/gemcitabine or carboplatin/paclitaxel starting 2 to 7 days after leukapheresis. after 6 cycles of chemotherapy, patients will start maintenance treatment with dcvac/ovca. treatment will continue irrespective of tumor progression until completion, refusal, intolerance of treatment or death.

Eligibility criteria:
inclusion criteria: * patients with histologically confirmed figo stage iii or iv epithelial ovarian, primary peritoneal or fallopian tube carcinoma (serous,endometrioid, or mucinous) who had complete remission after first-line platinum-based chemotherapy * radiologically confirmed relapse after \>6 months of remission ( platinum-sensitive cancer) * laboratory parameters per protocol exclusion criteria: * figo i, ii epithelial ovarian cancer * figo iii, iv clear cells epithelial ovarian cancer * non-epithelial ovarian cancer * borderline tumors ( tumors of low malignant potential) * prior or current systemic anti-cancer therapy for ovarian cancer (chemotherapy, monoclonal antibody therapy, tyrosine kinase inhibitory therapy, vascular endothelial growth factor or hormonal therapy) except first-line pt based chemotherapy ( with or without bevacizumab) * fertile women of child-bearing potential not willing to use a highly effective method of contraception or a combination of methods * pregnant of lactating women * pre-defined co-morbidities * known hypersensitivity to any constituent of dcvac/ovca or the selected chemotherapy compounds

Keywords: immunotherapy platinum-sensitive biologic vaccine ovarian cancer fallopian tube cancer primary peritoneal cancer dendritic cells chemotherapy leukapheresis figo iii figo iv
the effect of traditional mat exercises versus reformer pilates and hammock yoga on chronic back pain

Conditions: Low Back Pain

Summary: the purpose of the present study was to examine the effects of traditional mat exercises, reformer pilates and hammock yoga approaches on pain, endurance, balance, disability, and quality of life of individuals who had chronic back pain.

low back pain is among the leading musculoskeletal problems worldwide causing serious health expenditures. it can affect people of all ages in the community, but it is common in individuals between the fourth and fifth decades of life. low back pain is divided into 3 subclasses according to the duration of the symptoms as acute (lasting only a few weeks), subacute (lasting about 6 to 12 weeks), and chronic (lasting more than 12 weeks).traditional exercise approaches are frequently used modalities in the treatment of chronic back pain as an extremely valuable approach to preventing movement limitation, controlling existing pain, and regaining motor functions. pilates exercises are very valuable for the treatment of low back pain because they provide stabilization. pilates activates the lumbopelvic muscles and supports functional movement as an effective factor in reducing pain. yoga is also a mind-body exercise discipline that includes both physical and mental aspects of pain with core strengthening, flexibility, relaxation, and breathing modalities.when the literature was reviewed, no study was detected examining the effectiveness of hammock yoga and reformer pilates in people who have chronic back pain and compares it with traditional mat exercises.

Eligibility criteria:
inclusion criteria: * being within the 25-60 age range * having low back pain in the last 6 months . exclusion criteria: * the history of surgery in the lumbar region in the last 1 year, * diagnosed radiculopathy, * systemic diseases * malignancy, * performed regular physical activity, * using steroids and anti-inflammatory drugs in the physiotherapy program

Keywords: chronic back pain reformer pilates hammock yoga physical fitness quality of life
development of a mindfulness-based treatment for the reduction of alcohol use and smoking cessation

Conditions: Tobacco Use; Alcohol Use, Unspecified

Summary: the purpose of this study is to develop a treatment that can effectively help people reduce their alcohol use and quit smoking.

this study evaluates a mindfulness-based treatment to concurrently target cigarette smoking and alcohol use behaviors in adults. aim 1: modify an existing mindfulness-based treatment to include a focus on smoking cessation and reduced alcohol use. aim 2: evaluate benchmarks regarding the feasibility and acceptability of mindfulness based relapse prevention -smoking and alcohol use. aim 3: collect and examine descriptive data on proximal and distal variables associated with increased smoking abstinence and reduced drinking.

Eligibility criteria:
inclusion criteria aim 1: * 18 years of age or older * currently smoking 3 or more cigarettes per day for the past year. * carbon monoxide level \>/= 8 ppm(parts per million); should carbon monoxide level yield a result less than 8 ppm, participant will be asked to submit a urine sample to determine contine levels and the result must be \>/ level 3 * participant must be motivated to quit smoking and decrease alcohol use within the next 60 days * if male, consume \>/= 5 drinks and if female consume \>/= 4 drinks on at least 1 occasion in the past month * willing and able to attend the 8 weekly group sessions * valid home address in the tampa bay area * functioning telephone number * can speak, read and write in english inclusion criteria aim 2: * 18 years of age or older * currently smoking 3 or more cigarettes per day for the past year. * motivated to quit smoking and decrease alcohol use within the next 60 days * if male, consumes \>/= 5 drinks and if female consumes \>/= 4 drinks on at least 1 occasion in the past month * willingness and ability to attend 8 weekly video group sessions * willingness and ability to use an email account for study materials * valid address * functioning telephone number * can speak, read and write in english exclusion criteria: * unable to wear nicotine patch * participants who have an active substance use disorder other than an alcohol use disorder * participants who have an active psychotic disorder * current use of tobacco cessation medications * pregnant or nursing * participants who have a household member already enrolled in the study. * in rare cases, study staff might exclude a participant for a reason not specified here

Keywords: alcohol drinking quit smoking
patient education in adherence on acne (peace)

Conditions: Acne

Summary: this is a multi-center, randomised and controlled study in subjects with acne vulgaris. the main objective of this study is to evaluate the effect of a supplementary patient education intervention (in addition to the standard-of-care patient education) on treatment adherence and satisfaction among acne patients receiving once-daily epiduotm gel treatment in primary care clinics.


Eligibility criteria:
inclusion criteria: 1. male or female subjects age of 12 years or older, 2. with facial acne vulgaris that can be managed in primary care exclusion criteria: 1. female subjects who are pregnant, nursing or planning a pregnancy during the study, 2. subjects have a very severe variant of acne such as fulminating acne with systemic symptoms (acne fulminans)
amino acid bioavailability in healthy elderly after intake of an oral nutritional supplement

Conditions: Sarcopenia

Summary: in this study healthy older adults are requested to consume 4 different high-protein nutritional supplements. each subject will visit the site 4 times and at every visit they will consume 1 of the 4 products after which a series of blood samples will be taken. the blood samples will be analyzed for amino acid bioavailability in the blood up to 4 hours after consumption.


Eligibility criteria:
inclusion criteria: * age 65 years or older * bmi between 21 and 30 kg/m2 exclusion criteria: * any condition that may interfere with the definition 'healthy elderly' according to the investigator's judgement. * any (history of) gastrointestinal disease that interferes with gi function (e.g. inflammatory bowel disease, gastroparesis, gastrectomy). * known allergy to milk and milk products. * known galactosaemia. * current or recent (within past three months) smoking. * known or suspected diabetes mellitus. * current infection or fever in the last 7 days at the discretion of the physician. * use of antibiotics within 3 weeks of study entry. * current use of corticosteroids or hormones. * current use of antacids or any medication influencing gastric acid production. * requirement for any nutritional support. * unplanned body weight loss \> 5% in the past 3-6 months. * adherence to any specific diet (e.g. weight loss, vegetarian). * use of protein containing or amino acid containing nutritional supplements within one week of study entry. * alcohol or drug abuse. * investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements. * participation in any other study with investigational products concomitantly or within 4 weeks of study entry.

Keywords: bioavailability amino acids elderly supplement
tegmen defect management during mastoidectomy

Conditions: Chronic Otitis Media

Summary: in this study, we aimed to discuss our clinical experience on the management of the tegmen defects which were revealed during the mastoidectomy surgeries.


Eligibility criteria:
inclusion criteria: * underwent mastoidectomy as alone or as a part of the surgery, and noticed tegmen mastoideum or tympani defect in related department. exclusion criteria: * patients who did not come to follow up
¡salud! por la vida (splv) a colorectal screening promotion program

Conditions: Colorectal Cancer

Summary: the overall goal of this educational program was to increase colorectal cancer screening (crcs) in men and women who attend federally qualified health centers (fqhc) in puerto rico. fqhcs, referred to in puerto rico as "clínicas 330", are ideal settings to implement innovative approaches to increase crcs because they serve primarily low-income patients who typically have lower rates of screening. the goal of this study, is to develop and evaluate the impact of a clinic level intervention on increasing crcs among low-income puerto rican men and women aged 50-75, who have either never been screened for colorectal cancer, or are under-screened according recommended guidelines. to evaluate the delivery of the crcs education program we used a group randomized controlled trial that provided data to determine the effectiveness of the crc intervention program compared with usual practice (no intervention).


Eligibility criteria:
inclusion criteria: * female aged 50-75, patient at a participating fqhc. * male aged 50-75, patient at a participating fqhc. exclusion criteria: * having completed a fecal occult blood test (fobt) or a fecal immunochemical test (fit) in the past year. * having completed a sigmoidoscopy in the last 5 years. * having completed a colonoscopy in the last 10 years. * prior history of colorectal cancer.

Keywords: hispanic/latino behavioral intervention lay health workers colorectal cancer colorectal cancer screening colonoscopy cancer prevention
intraocular position of secondary iris-fixated iols in aphakic eyes

Conditions: Aphakia

Summary: the purpose of this study is to evaluate the intraocular stability and safety of secondary iris-fixated iols in aphakic patients.

18 eyes of 16 patients received secondary anteriorly iris-fixated intraocular lenses (iols) to correct for aphakia without capsular support, partly combined with anterior or complete pars plana vitrectomy. primary outcome measurements included visual acuity (6m snellen charts), central endothelium cell count (cecc) and postoperative intraocular position of the iol assessed with anterior segment optical coherence tomography (oct).

Eligibility criteria:
inclusion criteria: * patients with aphakia due to complicated cataract surgery, weakness in lens support (capsula, zonulae) marfans´s syndrome exclusion criteria: * aphakia due to preexisting corneal, retinal o uveal disease, low endothelial cell count

Keywords: aphakia secondary iol-implantation iris-fixated iol artisan anterior segment oct aphakia - secondary iris-fixated iol position
multi-omic assessment of squamous cell cancers receiving systemic therapy

Conditions: Cancer; Esophagus Squamous Cell Carcinoma; Squamous Cell Carcinoma of the Head and Neck; Anal Canal Squamous Cell Carcinoma; Metastatic Cancer

Summary: this is prospective research study which will include patients with recurrent or metastatic squamous cell carcinoma of the head and neck, esophagus and anal canal starting on first-line platinum based chemotherapy or any line of immunotherapy treatment.this study aims to characterize the dynamic changes in genomic, epigenetic, immune profiling and imaging data during treatment with systemic therapy. patients will have archived tumor samples requested as well as blood samples collected at up to four time points to analyze these changes. imaging data will be derived from patients' routine ct scans before and after treatment.


Eligibility criteria:
inclusion criteria: 1. patients with a histological or cytological diagnosis of squamous cell cancer of the head and neck, esophagus or anal canal who have radiologically confirmed recurrent or metastatic disease. 2. patients must be of adequate fitness, ecog 0-1 for systemic therapy, with either standard chemotherapy, immunotherapy or within the context of a clinical trial. 3. patients must be commencing on a new treatment at time of consent, this can be first line platinum based chemotherapy, or immunotherapy, any line. 4. patients must be ≥ 18 years old. 5. patients must have provided voluntary written informed consent. exclusion criteria: none

Keywords: liquid biopsy circulating tumor dna molecular profiling immune analysis epigenetics radiomics
effect of liraglutide in obese subjects with moderate or severe obstructive sleep apnoea: scale™ - sleep apnoea

Conditions: Metabolism and Nutrition Disorder; Obesity; Obstructive Sleep Apnoea

Summary: this trial is conducted in north america. the aim of the trial is to investigate the effect of liraglutide in obese subjects with sleep apnoea.


Eligibility criteria:
inclusion criteria: * informed consent * body mass index equal to or above 30 kg/m\^2 * stable body weight (less than 5% self-reported change during the previous 3 months) * diagnosis of moderate or severe obstructive sleep apnoea (osa) * unwilling or unable to use continuous positive airway pressure (cpap) (or other positive airway pressure) treatment. no cpap (or other positive airway pressure) treatment for at least four weeks prior to screening * ability and willingness to comply with all protocol procedures e.g. correct handling of trial product, compliance to visit schedule and dietary advice and complete trial related questionnaires exclusion criteria: * treatment with glucagon-like peptide-1 (glp-1) receptor agonists, dipeptidyl peptidase-4 inhibitors or insulin within the last 3 months prior to screening * diagnosis of type 1 or type 2 diabetes per judgement of the investigator * glycosylated haemoglobin (hba1c) equal to or above 6.5% * significant craniofacial abnormalities that may cause osa * respiratory and neuromuscular diseases that could interfere with the results of the trial in the opinion of the investigator * use of central stimulants, hypnotics, mirtazepine, opioids, trazodone within the previous 3 months prior to screening * obesity induced by drug treatment * treatment with pramlintide, sibutramine, orlistat, zonisamide, topiramate or phenteremine within the last 3 month prior to screening * previous surgical treatment for obesity * screening calcitonin equal to or above 50 ng/l * familial or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma * personal history of non-familial medullary thyroid carcinoma * history of chronic pancreatitis or idiopathic acute pancreatitis * history of major depressive disorder or suicide attempts * systolic blood pressure equal to or above 160 mmhg and/or diastolic blood pressure equal to or above 100 mmhg

Keywords: osa